SCHEMBL6322104

SCHEMBL6322104

Cc1[nH]c(/C=C2\C(=O)Nc3cccc(-c4cccc(CCO)c4)c32)c(C)c1CCC(=O)N1C[C@@H](C)N[C@@H](C)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.47
FGFR1 P11362 13/20 0.47
PDGFRB P09619 12/20 0.47
FLT3 P36888 4/20 0.47
AURKB Q96GD4 4/20 0.47
CHEK1 O14757 3/20 0.47
AURKA O14965 2/20 0.47
RET P07949 2/20 0.47
FLT1 P17948 2/20 0.47
MAP4K2 Q12851 2/20 0.47
STK3 Q13188 2/20 0.47
PRKAA1 Q13131 2/20 0.47
GAK O14976 1/20 0.47
RPS6KA5 O75582 1/20 0.47
RPS6KA4 O75676 1/20 0.47
LATS1 O95835 1/20 0.47
CSNK2A2 P19784 1/20 0.47
MAP2K2 P36507 1/20 0.47
ZAP70 P43403 1/20 0.47
MAP2K1 Q02750 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6328520 0.88 FGFR1 (0.51) KDRFGFR1PDGFRBFLT3AURKB
SCHEMBL6330101 0.88 KDR (0.50) KDRFGFR1PDGFRBFLT3AURKB
SCHEMBL6324346 0.88 KDR (0.50) KDRFGFR1PDGFRBFLT3AURKB
SCHEMBL6322677 0.88 KDR (0.50) KDRFGFR1PDGFRBFLT3AURKB
SCHEMBL6324365 0.88 KDR (0.50) KDRFGFR1PDGFRBFLT3AURKB
SCHEMBL6322670 0.88 KDR (0.50) KDRFGFR1PDGFRBFLT3AURKB
SCHEMBL6327070 0.88 KDR (0.50) KDRFGFR1PDGFRBFLT3AURKB
SCHEMBL6322659 0.88 KDR (0.50) KDRFGFR1PDGFRBFLT3AURKB
SCHEMBL6327078 0.88 KDR (0.50) KDRFGFR1PDGFRBFLT3AURKB
SCHEMBL6330099 0.88 KDR (0.50) KDRFGFR1PDGFRBFLT3AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885FGFR1 525/4885PDGFRB 575/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885FGFR1 525/4885PDGFRB 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.